ClinicalTrials.gg
RecruitingNCT07606703Updated May 26, 2026

A Prospective Study of Madecassoside Tablets in Sclerotic Chronic Graft-versus-Host Disease After Allo-HSCT

A Phase 2 interventional study of Madecassoside Tablets and Standard Therapy in Chronic Graft-Versus-Host Disease and Graft vs Host Disease, sponsored by WeiShi. Recruiting at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-26.

Sponsored by WeiShi · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2025, registered May 2026).
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
14 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China — 19 open to participants now, 25 under way, 2 of them phase 3. Bronchiolitis Obliterans Syndrome · China.

Planned enrollment
28th of 42
30 · median 50
Started
2025
with 9 others
Phase 2
14 of 52
6 open now
Primary completion
2028-03
later than 16 of 24 live
Registered
49th of 52
by date

Among the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, this one is the 28th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 16 of the 24 other live ones, and was the 49th registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

19 of the 52 studies in Bronchiolitis Obliterans Syndrome with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 14 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Bronchiolitis Obliterans Syndrome with a site in China, or all of them as a file.
02

Study summary

Sclerotic chronic graft-versus-host disease (scl-cGVHD) is a severe subtype of chronic GVHD after allogeneic hematopoietic stem cell transplantation (allo-HSCT), characterized by skin sclerosis, fascial involvement, and restricted joint mobility, leading to substantial functional impairment and reduced quality of life. Current standard therapies, including corticosteroids and other immunosuppressive agents, have limited efficacy in patients with refractory or steroid-dependent disease.

Madecassoside tablets, a standardized extract of Centella asiatica, have demonstrated anti-inflammatory and anti-fibrotic properties in previous studies and may provide therapeutic benefit in fibrotic diseases.

This study is a prospective, multicenter, single-arm phase 2 clinical trial designed to evaluate the efficacy and safety of madecassoside tablets combined with standard therapy in patients with scl-cGVHD after allo-HSCT. Eligible participants will receive oral madecassoside tablets (0.2 g three times daily) in addition to standard treatment for 6 months. Clinical assessments will be performed at baseline and at weeks 4, 8, 12, and 24.

The primary endpoint is the improvement rate of skin and/or joint/fascia NIH cGVHD scores at 6 months according to the 2014 NIH consensus criteria. Secondary endpoints include overall cGVHD response rate, failure-free survival, non-relapse mortality, corticosteroid dose reduction, patient-reported outcomes, and safety assessments. Peripheral blood samples will also be collected to explore changes in inflammatory cytokines and lymphocyte subsets during treatment.

03

Conditions studied

  • Chronic Graft-Versus-Host Disease
  • Graft vs Host Disease
04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and willingness to sign written ;
  2. Age 14 to 65 years;
  3. Diagnosis of sclerotic chronic (scl-cGVHD) according to the 2014 NIH consensus criteria, including superficial or deep skin sclerosis, fasciitis, or restricted joint mobility;
  4. Prior treatment history meeting at least one of the following:

    • Received systemic therapy for ≥12 months and at least 1 additional systemic therapy; OR
    • Received corticosteroid therapy and at least 2 additional systemic therapies;
  5. Performance Status (KPS) score ≥60;
  6. >1,000/μL;
  7. count ≥50,000/μL.

Exclusion criteria

Exclusion Criteria:

  • 1. Total >1.5 times the ; 2. \<30 mL/min; 3. Uncontrolled infection; 4. Uncontrolled cardiovascular or pulmonary disease; 5. Any clinical condition that, in the investigator's judgment, makes the participant unsuitable for study participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental: Madecassoside Tablets Plus Standard Therapy

    Drug: Madecassoside Tablets · Drug: Standard Therapy

Interventions

  • DrugMadecassoside Tablets

    Madecassoside tablets will be administered orally at a dose of 0.2 g (2 tablets) three times daily for 6 months in combination with standard therapy.

  • DrugStandard Therapy

    Standard therapy may include corticosteroids, calcineurin inhibitors, ruxolitinib, belumosudil, topical medications, and supportive care according to institutional guidelines and physician discretion.

06

What researchers measure

Primary outcomes

  1. Change in Skin and/or Joint/Fascia NIH cGVHD Scores

    The proportion of participants achieving complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) in skin and/or joint/fascia manifestations according to the 2014 NIH chronic graft-versus-host disease response criteria after 6 months of treatment.

    Time frame: 6 months

Secondary outcomes

  1. Overall cGVHD Response Rate

    Overall response rate of chronic graft-versus-host disease based on the 2014 NIH response criteria.

    Time frame: 6 months

  2. Failure-Free Survival

    Failure-free survival defined as survival without relapse, non-relapse mortality, or addition of new systemic therapy.

    Time frame: 2 years

  3. Non-Relapse Mortality

    Incidence of death without relapse of the underlying disease during follow-up.

    Time frame: 2 years

  4. Corticosteroid Dose Reduction

    Proportion of participants achieving at least 50% reduction or discontinuation of corticosteroid therapy.

    Time frame: 6 months

  5. Patient-Reported Outcomes

    Changes in patient-reported outcomes including Lee Symptom Scale (LSS), Scleroderma Health Assessment Questionnaire (SHAQ), and Photographic Range of Motion (P-ROM) scores.

    Time frame: Baseline to 6 months

  6. Traditional Chinese Medicine Symptom Score

    Changes in Traditional Chinese Medicine symptom scores during treatment.

    Time frame: Baseline to 6 months

  7. Safety and Adverse Events

    Incidence and severity of adverse events assessed according to CTCAE version 5.0.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2028, 30 months after the start.

Of 38 non-industry phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 70. This study's planned 30 months is below that.

Counting every sponsor, half of 63 studies reached it within 35 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2026
First posted
May 26, 2026
StartActual
Sep 1, 2025
Primary completionEst.
Mar 1, 2028
CompletionEst.
Sep 1, 2029
Last update
May 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606703
Lead sponsor
WeiShi
Responsible party
WeiShi (Chief Physician, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Sponsor-investigator
First posted
May 26, 2026
Start date
Sep 1, 2025
Primary completion
Mar 1, 2028 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
May 26, 2026

Study contacts

wei MD, PhD
Contact
shiwei076@hust.edu.cn
+86 027-85726003

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion